Home
XNCR
XNCR News

Latest Xencor Inc. (XNCR) News on June 8, 2025

Argus Research

18 days ago

XNCR: What does Argus have to say about XNCR?

Argus Research

25 days ago

XNCR: What does Argus have to say about XNCR?

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a month ago

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

a month ago

Xencor: Q1 Earnings Snapshot

Xencor Reports First Quarter 2025 Financial Results

Business Wire

a month ago

Xencor Reports First Quarter 2025 Financial Results

Argus Research

a month ago

XNCR: Lowering target price to $9.00

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Zacks

a month ago

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Business Wire

a month ago

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Argus Research

2 months ago

XNCR: Raising target price to $11.00

MT Newswires

2 months ago

William Blair Initiates Xencor at Outperform

Argus Research

2 months ago

XNCR: Raising target price to $10.00

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 04/15/2025

Xencor (XNCR) Upgraded to Buy: Here's Why

Zacks

2 months ago

Xencor (XNCR) Upgraded to Buy: Here's Why

Argus Research

2 months ago

XNCR: Lowering target price to $8.00

Argus Research

2 months ago

XNCR: Lowering target price to $10.00

Argus Research

2 months ago

XNCR: Lowering target price to $12.00

Xencor Appoints Todd Simpson to Board of Directors

Business Wire

3 months ago

Xencor Appoints Todd Simpson to Board of Directors

MT Newswires

3 months ago

Xencor Insider Sold Shares Worth $268,080, According to a Recent SEC Filing

Argus Research

3 months ago

XNCR: What does Argus have to say about XNCR?

MT Newswires

3 months ago

RBC Capital Adjusts Xencor Price Target to $32 From $34, Maintains Outperform - Speculative Risk Rating

MT Newswires

3 months ago

Wedbush Cuts Price Target on Xencor to $31 From $38, Keeps Outperform Rating

Xencor Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Xencor Full Year 2024 Earnings: Beats Expectations

MT Newswires

3 months ago

Xencor's Q4 Net Loss Widens, Revenue Rises

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Zacks

3 months ago

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

3 months ago

Xencor: Q4 Earnings Snapshot

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Business Wire

3 months ago

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Argus Research

3 months ago

XNCR: Lowering target price to $15.00

Argus Research

4 months ago

XNCR: What does Argus have to say about XNCR?

Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

4 months ago

Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Argus Research

4 months ago

XNCR: Lowering target price to $19.00

Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week

Simply Wall St.

4 months ago

Xencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past week

Argus Research

4 months ago

XNCR: Lowering target price to $20.00

Argus Research

5 months ago

XNCR: Raising target price to $21.00

Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

Zacks

5 months ago

Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

Zacks

5 months ago

After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

Zacks

5 months ago

Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks

Argus Research

5 months ago

XNCR: Lowering target price to $20.00

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Zacks

5 months ago

Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know

Argus Research

5 months ago

XNCR: What does Argus have to say about XNCR?

Argus Research

6 months ago

XNCR: Rating increased to a HOLD

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

Zacks

6 months ago

All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy

MT Newswires

6 months ago

Wells Fargo Initiates Xencor at Overweight With $37 Price Target

Argus Research

6 months ago

XNCR: Lowering target price to $23.00

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

Zacks

6 months ago

Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet

Argus Research

6 months ago

XNCR: Raising target price to $24.00

MT Newswires

6 months ago

Piper Sandler Upgrades Xencor to Overweight, Price Target is $30

Argus Research

6 months ago

XNCR: Raising target price to $23.00

Xencor to Participate at Upcoming Investor Conferences

Business Wire

6 months ago

Xencor to Participate at Upcoming Investor Conferences

MT Newswires

7 months ago

Top Premarket Gainers

Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade

Zacks

7 months ago

Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

Zacks

7 months ago

Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross

MT Newswires

7 months ago

Xencor Insider Sold Shares Worth $1,612,639, According to a Recent SEC Filing

Argus Research

7 months ago

XNCR: Raising target price to $25.00

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Simply Wall St.

7 months ago

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Zacks

7 months ago

Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

7 months ago

Xencor: Q3 Earnings Snapshot

Xencor Reports Third Quarter 2024 Financial Results

Business Wire

7 months ago

Xencor Reports Third Quarter 2024 Financial Results

Argus Research

7 months ago

XNCR: What does Argus have to say about XNCR?

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Business Wire

7 months ago

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?

Zacks

7 months ago

Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

Zacks

7 months ago

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

7 months ago

Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?

State Street Corp's Strategic Reduction in Xencor Inc Holdings

GuruFocus.com

8 months ago

State Street Corp's Strategic Reduction in Xencor Inc Holdings

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know

Zacks

8 months ago

Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Business Wire

8 months ago

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Argus Research

8 months ago

XNCR: What does Argus have to say about XNCR?

Xencor Announces Upcoming Change to Board of Directors

Business Wire

8 months ago

Xencor Announces Upcoming Change to Board of Directors

MT Newswires

8 months ago

RBC Raises Price Target on Xencor to $34 From $31, Keeps Outperform, Speculative Risk

MT Newswires

9 months ago

Xencor Raises $201.3 Million From Public Offering

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Business Wire

9 months ago

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?

Zacks

9 months ago

Xencor (XNCR) Surges 10.5%: Is This an Indication of Further Gains?

MT Newswires

9 months ago

Xencor Prices $175 Million Public Stock Offering

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Business Wire

9 months ago

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

MT Newswires

9 months ago

Xencor Launching Stock Sale; Shares Lower After-Hours

Xencor Announces Proposed Public Offering of Common Stock

Business Wire

9 months ago

Xencor Announces Proposed Public Offering of Common Stock

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

Zacks

9 months ago

Xencor Stock Gains 23% on Encouraging Pipeline Advancements

MT Newswires

9 months ago

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires

9 months ago

Sector Update: Health Care Stocks Rise Monday Afternoon

MT Newswires

9 months ago

Xencor Shares Rise After 4 New Drug Candidates for Autoimmune, Inflammatory Diseases Announced

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Business Wire

9 months ago

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Business Wire

9 months ago

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Argus Research

9 months ago

XNCR: What does Argus have to say about XNCR?

Argus Research

10 months ago

XNCR: Raising target price to $18.00

Estimating The Intrinsic Value Of Xencor, Inc. (NASDAQ:XNCR)

Simply Wall St.

10 months ago

Estimating The Intrinsic Value Of Xencor, Inc. (NASDAQ:XNCR)

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Zacks

10 months ago

Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

10 months ago

Xencor: Q2 Earnings Snapshot

Xencor Reports Second Quarter 2024 Financial Results

Business Wire

10 months ago

Xencor Reports Second Quarter 2024 Financial Results

Argus Research

10 months ago

XNCR: What does Argus have to say about XNCR?

Argus Research

a year ago

XNCR: Raising target price to $21.00

Argus Research

a year ago

XNCR: What does Argus have to say about XNCR?

Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago

Simply Wall St.

a year ago

Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago

MT Newswires

a year ago

Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating

MT Newswires

a year ago

BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating

MT Newswires

a year ago

RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating

MT Newswires

a year ago

Wedbush Cuts Price Target on Xencor to $34 From $36, Maintains Outperform Rating

MT Newswires

a year ago

Xencor to Regain Exclusive Global Rights to CD20 x CD3 Bispecific T-Cell Engager

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

Business Wire

a year ago

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

a year ago

The Best Woody Perfume For Women

Share on Social Networks: